eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

ELIQUIS (apixaban) dosing for patients with DVT / PE

ELIQUIS for the treatment of DVT / PE and prevention of recurrent DVT / PE

The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding.1

ELIQUIS indications1

Dose1

knee-icon

Morning*

knee-icon

Night*

knee-iconlung-icon

DVT / PE treatment: treatment of DVT and PE in adults

Day 1–7:
10 mg BD

5mgTablet-icon5mgTablet-icon
ELIQUIS 5 mg x2

5mgTablet-icon5mgTablet-icon
ELIQUIS 5 mg x2

Day 8 onwards:
5 mg BD
for at least 3 months
Short duration of treatment (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation).1


knee-icon
ELIQUIS 5 mg

knee-icon
ELIQUIS 5 mg

combined-Lung-knee-icon

Prevention of recurrent DVT / PE: prevention of recurrent DVT and / or PE in adults following completion of 6 months of treatment with ELIQUIS 5 mg BD or with another anticoagulant treatment for DVT or PE

2.5 mg BD

knee-icon
ELIQUIS 2.5 mg

knee-icon
ELIQUIS 2.5 mg

* Tablets shown are not actual size.

  • Eliquis is not recommended in patients with CrCl <15ml/min or in patients undergoing dialysis
  • The use of Eliquis is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp. For the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT/PE, Eliquis should be used with caution in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp. For the treatment of DVT /PE, in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp, Eliquis should not be used since efficacy may be compromised. See SmPC for complete information on drug-drug interactions.
Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

BD = Twice Daily   CrCl = Creatinine Clearance   CYP3A4 = Cytochrome P450 3A4   DVT = Deep Vein Thrombosis   INR = International Normalised Ratio   LMWH = Low Molecular Weight Heparin   PE = Pulmonary Embolism   P-gp = P-glycoprotein

Reference

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.